<div id="readability-page-1">10:44 AM EST, 11/10/2025 (MT Newswires) -- InflaRx ( IFRX ) said Monday that a phase 2a study evaluating INF904 in hidradenitis suppurative, or HS, and chronic spontaneous urticaria, or CSU, demonstrated improvements in clinical endpoints, supporting its further development in both indications.Clinical endpoints for HS include reduction in abscesses and nodules, and draining tunnels, which the product candidate achieved, InflaRx ( IFRX ) said. In CSU, InflaRx ( IFRX ) said it observed &#34;substantial&#34; reductions in patients' seven-day Urticaria Activity Score, among other endpoints.The company said it intends to complete the four-week post-treatment observation period under the phase 2a study and plans to advance clinical development to a phase 2b trial in 2026.Shares of InflaRx ( IFRX ) were up more than 26% in recent Monday trading.Price: 1.56, Change: +0.33, Percent Change: +26.83 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

IFRX

InflaRx (IFRX) announced positive results from a Phase 2a study of INF904 for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), showing improvements in clinical endpoints. The company plans to proceed to a Phase 2b trial in 2026 after completing a four-week post-treatment observation. Following the announcement, shares of InflaRx rose over 26% in trading.

InflaRx Says Phase 2a Data Support Further Development of INF904 in 2 Skin Conditions